Abstract-The heart manifests hypertrophic growth in response to elevation of afterload pressure. Cardiac myocyte growth involves new protein synthesis and membrane expansion, of which a number of cellular quality control machineries are stimulated to maintain function and homeostasis. The unfolded protein response is potently induced during cardiac hypertrophy to enhance protein-folding capacity and eliminate terminally misfolded proteins. However, whether the unfolded protein response directly regulates cardiac myocyte growth remains to be fully determined. Here, we show that GRP78 (glucose-regulated protein of 78 kDa)-an endoplasmic reticulum-resident chaperone and a critical unfolded protein response regulator-is induced by cardiac hypertrophy. Importantly, overexpression of GRP78 in cardiomyocytes is sufficient to potentiate hypertrophic stimulus-triggered growth. At the in vivo level, TG (transgenic) hearts overexpressing GRP78 mount elevated hypertrophic growth in response to pressure overload. We went further to show that GRP78 increases GATA4 (GATA-binding protein 4) level, which may stimulate Anf (atrial natriuretic factor) expression and promote cardiac hypertrophic growth. Silencing of GATA4 in cultured neonatal rat ventricular myocytes significantly diminishes GRP78-mediated growth response. Our results, therefore, reveal that protein-folding chaperone GRP78 may directly enhance cardiomyocyte growth by stimulating cardiac-specific transcriptional factor GATA4. (Hypertension.
A pproximately, one-third of adults ≥18 years of age are affected by high blood pressure. 1 This number is even higher among elderly. Numerous epidemiological studies have shown that hypertension causes severe complications and represents a major risk factor of heart disease, stroke, and death. 2 In response to elevated blood pressure, the heart manifests hypertrophic growth to ameliorate ventricular wall stress and maintains cardiac performance to ensure homeostatic perfusion of the body. 3 Because of limited proliferating capacity in adult stage, the heart does so by enlarging individual cardiomyocytes. This concentric growth leads to increases in cardiac mass and enhancement of pumping function. 4 Hypertrophic growth, however, is above and beyond simple addition of sarcomeres. A myriad of signaling molecules need to coordinate and orchestrate the growth response for normal cardiac performance. 4 Over the years, a complex network of pathways has been identified in this process, including calcium handling, 5 metabolism, 6 excitation-contraction coupling, 7 growth signaling, 8 etc.
Increases in protein biosynthesis during cardiac hypertrophic growth lead to activation of the unfolded protein response (UPR)-a cellular adaptive process to accommodate the augmented demands in protein folding. 9 Under resting conditions, minimal protein-folding requirement is maintained in the endoplasmic reticulum (ER) by a host of chaperones, foldases, oxidoreductases, isomerases, etc. 10 Glucose-regulated protein of 78 kDa (GRP78)-the most abundant ER-resident chaperone-interacts with luminal domains of the 3 signaling transducers, PERK (protein kinase R-like ER kinase), IRE1 (inositol-requiring enzyme 1), and ATF6 (activating transcriptional factor 6). These interactions sequester the transducers from activation and downstream actions. On accumulation of misfolded proteins in the ER, GRP78 preferentially binds the exposed hydrophobic domains in client proteins and, therefore, liberates the 3 signaling branches. As a result, the UPR transiently reduces protein translation to decrease ER load, upregulates protein chaperones, and stimulates ER-associated protein degradation to eliminate terminally misfolded proteins. In so doing, the balance of protein-folding capacity and demands is regained, thereby maintaining ER homeostasis.
The UPR plays critical roles in the initiation and development of cardiovascular disease, including myocardial infarction, ischemia/reperfusion, diabetic cardiomyopathy, etc. [11] [12] [13] In hypertensive heart disease, most prior studies focus on the protein quality control action of the UPR. However, emerging evidence points to additional layers of regulation above and beyond protein folding. Early work by Okada et al 14 shows that excessive activation of CHOP (C/EBP homologous protein)-a downstream effector of the UPR-by pressure overload leads to apoptotic cardiac cell death and heart failure. Indeed, ablation of CHOP ameliorates pathological cardiac remodeling and regresses disease progression. 15 In contrast, PERK deficiency in the heart exacerbates cardiac dysfunction by pressure overload. 16 On the contrary, Belmont et al 17 found that ATF6 may counteract cardiac hypertrophic growth by directly stimulating Rcan1 (regulator of calcineurin 1) in cultured cardiac myocytes. Considering the versatile role of the UPR in metabolism, cell growth and apoptosis in addition to protein quality control, it is possible that the UPR directly regulate cardiac hypertrophic growth in response to hemodynamic stress.
GRP78 is an essential, ER-resident protein chaperone. 18 Accumulating studies have shown that GRP78 plays critical roles in the heart under both physiological and pathological conditions. 19 Using genetically engineered animal models, we found that GRP78 deficiency in cardiomyocytes leads to cardiac dilation, heart failure, and early mortality. 20 GRP78 expression is augmented by myocardial infarction 21 and cardiac ischemia/ reperfusion. 22 We recently showed that overexpression of GRP78 in cardiomyocytes protects the heart from reperfusion injury via activation of the prosurviving AKT (RAC-alpha serine/threonine-protein kinase) signal. 23 Despite these findings, our understanding of GRP78 in hypertensive heart disease remains vacant. Here, we sought to elucidate the role of GRP78 in the heart in response to pressure overload using both animal models and primary cardiac myocyte culture.
Materials and Methods
The data, methods, and materials that support the findings of this study are available from the corresponding author on reasonable request.
Animals
All mice were on C57BL/6 background. Animals were maintained on a 12-hour dark/light cycle (6 am to 6 pm) and housed in a barrier facility with unlimited access to chow food (2916; Teklad) and water. The Institutional Animal Care and the Use Committee of University of Texas Southwestern Medical Center has approved all animal experiments. Genotyping primers are provided in Table S1 in the online-only Data Supplement.
Statistics
Statistical analysis was performed using GraphPad Prism 7. Data are expressed as mean±SEM. The student t test (2 tailed) was performed to compare difference between 2 groups. Additionally, 1-way or 2-way ANOVA was used for multiple groups, followed by Tukey test. P <0.05 was considered statistically significant.
Results

Induction of GRP78 by Pressure Overload in the Heart
GRP78 is an essential protein chaperone localized in the ER and the master regulator of the UPR, which plays critical roles in physiology and pathophysiology. 18 In the heart, GRP78 expression is upregulated during cardiogenesis, and elimination of GRP78 in cardiomyocytes is not compatible with life. 24, 25 Here, we set out to investigate the role of GRP78 during cardiac hypertrophic growth under pressure overload.
We subjected WT (wild type) adult mice to thoracic aortic constriction (TAC), which creates aortic stenosis and mimics clinical situations of high blood pressure. The pressure gradient across aortic constriction site was determined 24 hours post-surgery ( Figure S1A ). We have shown previously that TAC leads to significant cardiac hypertrophic growth in a time-dependent manner. 26 The early phase of adaptive growth may progress into decompensation and heart failure. We harvested the hearts 7 days post-TAC and subjected to immunoblotting. Rcan1.4 (regulator of calcineurin 1.4) is a transcriptional target of calcineurin signaling and commonly used as a molecular marker of hypertrophic growth. 27 As positive controls, we found significant increases in the expression of βMHC (β-myosin heavy chain), Anf (atrial natriuretic factor), and Rcan1.4 ( Figure 1A and 1B), indicating robust and prominent hypertrophic growth. 26 Importantly, GRP78 expression was strongly induced. We next turned to cultured cardiac myocytes to validate GRP78 induction by hypertrophic growth. Neonatal rat ventricular myocytes (NRVMs) were isolated from day 1 and 2 newly born rats. We treated the cells with phenylephrine (PE; 50 μM) to stimulate cellular hypertrophy for 24 hours. We found that GRP78 was significantly elevated ( Figure 1C and 1D ). Taken together, these results suggest that GRP78 as a UPR marker is upregulated in response to cardiac cell hypertrophic growth.
Overexpression of GRP78 Promotes Hypertrophic Growth in the Heart
We next took an in vivo approach to investigate the role of GRP78 in cardiac hypertrophy. We generated a TG (transgenic) mouse model with GRP78 under control of the universal CAG (cytomegalovirus enhancer, chicken beta-actin promoter and rabbit beta-globin splice acceptor site) promoter. 23 A loxP siteflanked transcriptional/translational stop cassette was inserted between the promoter and GRP78. We crossed this TG mouse model with the cardiomyocyte-restricted αMHC-Cre TG animal. Cre-mediated cleavage of the stop cassette led to expression of GRP78 only in cardiac myocytes ( Figure S1B ).
We subjected double TG mice, along with littermate single TG controls, to TAC surgery for a week. Pressure gradient was measured that showed no detectable difference between control and TG mice ( Figure S1C ), indicating the surgery was similarly performed. We found that TG animals manifested significantly more severe cardiac hypertrophy and elevated fibrosis ( Figure 2A ; Figure S1D ). Individual cardiac myocytes were strongly enlarged ( Figure 2B and 2C). Indeed, the ratio of heart weight-to-body weight was higher in TG TAC mice compared with controls ( Figure 2D and 2E). Collectively, these data suggest that overexpression of GRP78 in cardiomyocytes leads to more profound cardiac hypertrophic response to pressure overload in vivo.
Overexpression of GRP78 Exacerbates Cardiac Response to Pressure Overload
We next set up to examine cardiac function using echocardiography with gently constrained, conscious mice. TG animals showed increased cardiac chamber size ( Figure 3A ). Cardiac function was impaired as indicated by depressed fractional shortening and ejection fraction ( Figure 3B ; Figure S2A ), whereas heart rate was maintained. The αMHC-Cre TGs alone did not affect cardiac function ( Figure S2B ). Further analysis showed increases in left ventricular internal diameter at both systole and diastole ( Figure 3B ), indicating a decline for systolic and diastolic performance. Consistently, diastolic and systolic interventricular septum and left ventricular posterior wall were reduced. Moreover, cardiac function showed further deterioration 3 weeks post-TAC ( Figure S2C ). In aggregate, these results indicate that GRP78 overexpression causes an exacerbated response to pressure overload. Induction of GRP78 (glucose-regulated protein of 78 kDa) by pressure overload in the heart. A, GRP78 protein expression was increased in the heart in response to pressure overload. Thoracic aortic constriction (TAC) was performed to induce cardiac hypertrophy. Note that multiple protein makers of cardiac hypertrophy show strong upregulation. GAPDH was used as a loading control. B, Quantification of (A) supported significant elevation of GRP78 by pressure overload. n=6. C, GRP78 was upregulated in cardiac myocytes by hypertrophy stimulation. Cultured neonatal rat ventricular myocytes were treated with phenylephrine (50 μM) for 24 h. GRP78 was detected by Western blotting (WB). Phenylephrine (PE) treatment stimulated cellular hypertrophic growth as indicated by increases in βMHC (β-myosin heavy chain), Rcan1.4 (regulator of calcineurin 1.4), and Anf (atrial natriuretic factor). D, Quantification of (C) showed significant upregulation of GRP78. Rcan1.1 indicates regulator of calcineurin 1.1; and veh, vehicle. n=5. *P<0.05, **P<0.01.
Figure 2.
Overexpression of GRP78 (glucose-regulated protein of 78 kDa) promotes hypertrophic growth in the heart. A, Ctrl (control) and TG (transgenic) mice were subjected to sham or thoracic aortic constriction (TAC) surgery. Hematoxylin and eosin staining showed more enlargement of the transgenic heart compared with ctrl. Masson Trichrome staining suggested an increase in fibrosis of the TG heart. Scale bar, 2 mm. B, Cardiac sections were used for wheat germ agglutinin staining to visualize individual cells in the heart. Scale bar, 50 μm. C, GRP78 overexpression led to significant increases in cardiac cell size after TAC. n=120 to 133. D, Overexpression of GRP78 in cardiomyocytes caused elevation in the ratio of heart weight (HW) to body weight (BW), indicating more profound cardiac hypertrophic growth. n=5 to 9. E, Quantification of HW/tibia length (TL) showed a trend of increase in the transgenic hearts compared with ctrl. n=5 to 9. *P<0.05, ***P<0.001.
Heart failure is presented clinically by the inability of the heart to pump blood and provide sufficient perfusion to the body. Here, we found that overexpression of GRP78 in cardiomyocytes caused heart failure after pressure overload. As a signature, ratio of wet lung weight to either body weight or tibia length ( Figure 3B ) was significantly elevated in GRP78 TGs. At the cellular level, molecular markers of heart failure were strongly induced, including Anf and Bnp ( Figure 3C through 3E). Quantitative polymerase chain reaction analysis confirmed the upregulation of these genes at the mRNA level ( Figure 3F ). Consistent with an aggravated response to pressure overload, Ctgf (connective tissue growth factor) as a marker of fibrosis was significantly increased ( Figure 3F ). In contrast, inflammatory genes were not significantly elevated in the TG hearts after TAC compared with controls ( Figure  S2D ). No detectable increase of apoptosis was discovered ( Figure S2E ). Under overexpression of GRP78 at this level in the heart, the ER stress response was not altered ( Figure  S3A through S3C) . Interestingly, we did not find significant difference in mTOR, AKT, or ERK (extracellular signal-regulated kinase) between control and TG mice after TAC ( Figure  S3B and S3C), suggesting this signaling may not contribute to the enhanced hypertrophic growth in GRP78 TG mice. On the contrary, phosphorylation of NFATc3 (nuclear factor of activated T cells c3) and p38 only showed a trend of decrease in the TG heart after TAC ( Figure S3B and S3C) , which may not play a major role in the prohypertrophic response in GRP78 TG mice. Our results collectively show that GRP78 overexpression in cardiomyocytes in vivo leads to exacerbation in cardiac response to pressure overload and heart failure.
Overexpression of GRP78 Increases Cardiomyocyte Hypertrophic Growth In Vitro
We next turned to cell culture to address whether the prohypertrophic action of GRP78 in cardiomyocytes was a cellautonomous phenomenon. We overexpressed GRP78 by adenovirus infection in NRVMs. We then treated the cells with PE for 24 hours. We found that overexpression of GRP78 Figure 3 . Overexpression of GRP78 (glucose-regulated protein of 78 kDa) exacerbates cardiac response to pressure overload. A, Representative M-mode images of echocardiography from conscious animals. B, GRP78 overexpression in the heart led to cardiac dysfunction and heart failure as shown by echocardiographic parameters and relative lung weight. n=5 to 17. Comparison was done between ctrl (control) and TG (transgenic) groups after thoracic aortic constriction (TAC). C, Transgenic mice showed elevation of Anf (atrial natriuretic factor) and Bnp (brain natriuretic peptide)-molecular markers of heart failure. D, Quantification of (C) indicated significant augmentation of Anf protein level in the transgenic hearts. n=4. E, Bnp protein level was significantly upregulated in the transgenic mice compared with ctrl. n=4. F, Anf and Ctgf (connective tissue growth factor) mRNA levels were strongly increased in the transgenic hearts in response to TAC, whereas Bnp mRNA showed a trend of upregulation. n=4 to 6. IVS indicates interventricular septum; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall; NS, not significant; Rcan1.1, regulator of calcineurin 1.1; Rcan1.4, regulator of calcineurin 1.4; and WB, Western blot. *P<0.05, ***P<0.001. February 2019 per se in NRVMs did not affect cardiac cell size, which, however, potentiated the response to PE (Figure 4A and 4B). To further corroborate this finding, we performed a leucine incorporation assay to assess protein synthesis. Consistently, overexpression of GRP78 in NRVMs led to a higher increase in protein synthesis after PE treatment ( Figure 4C) . At the cellular level, we found that Anf expression was further increased at both protein ( Figure 4D and 4E) and mRNA ( Figure 4F ) levels. Consistent with the in vivo data, no differences were found in mTOR, AKT, ERK, p38, or NFAT ( Figure S4A and S4B ). Furthermore, we tested another hypertrophic stimulus, angiotensin II. Likewise, overexpression of GRP78 led to more profound increases in cell size after angiotensin II treatment ( Figure S5A and S5B), which was not accompanied by elevation of p38 phosphorylation ( Figure S5C and S5D) . Taken together, these results suggest that overexpression of GRP78 enhances growth response to hypertrophic stimuli at cellular level.
Knockdown of GRP78 Inhibits Cardiomyocyte Hypertrophic Response In Vitro
We next asked the question about requirement of GRP78 in the hypertrophic response. We silenced GRP78 by siRNA transfection. After PE treatment, cells were harvested for cell size determination. Knockdown of GRP78 significantly diminished hypertrophic response to PE ( Figure 5A and 5B), which was consistent with decreased protein synthesis rate ( Figure 5C) . At the molecular level, we found that induction of Anf by PE was strongly inhibited at both protein ( Figure 5D and 5E) and mRNA ( Figure 5F ) levels. Collectively, these data lend further support that GRP78 is critical to promote cardiac cell growth in response to hypertrophy stimulation.
GATA4 Is Required for GRP78-Mediated Promotion of Hypertrophic Growth
GATA4 (GATA-binding protein 4) belongs to a family of transcriptional factors binding to GATA DNA motif. GATA4 plays an essential role in cardiogenesis during embryonic development. 28 Deficiency of GATA4 leads to severe congenital heart disease and heart failure. Furthermore, GATA4 is a key regulator of hypertrophic growth in response to pressure overload. 18, 29 We, therefore, asked the question whether GATA4 was involved in GRP78-mediated cardiac hypertrophic growth. We found that GATA4 protein level was significantly elevated in the GRP78 TG mice after TAC ( Figure 6A ). In NRVMs, GATA4 was increased by GRP78 overexpression after PE treatment ( Figure 6B ), indicating a cell-autonomous phenomenon. Importantly, silencing of GRP78 decreased the protein level of GATA4 after PE administration ( Figure 6C ). These results indicate GATA4 protein level is correlated with GRP78 expression in cardiac myocytes in response to hypertrophy stimulation.
To further define the relationship between GRP78 and GATA4, we overexpressed GRP78 in NRVMs by adenovirus infection. We then silenced GATA4 by siRNA transfection. After PE treatment, we found that GRP78 overexpression led to more profound hypertrophic growth, which was significantly suppressed by GATA4 knockdown ( Figure 6D ). Consistent with these findings, Anf expression was diminished by GATA4 silencing ( Figure 6E ). We next set out to examine whether GRP78 could enhance the transcriptional activity of GATA4 on Anf. We performed a luciferase assay in HEK-293T cells. We transfected the Anf-luciferase plasmid along with either control pcDNA3.1 or pcDNA3.1-GATA4 construct. Expression of GATA4 stimulated Anf-luciferase activity ( Figure 6F ). Importantly, overexpression of GRP78 under this condition led to further augmentation of the Anf promoter activity. Importantly, MEF2a (myocyte enhancer factor 2a)-mediated upregulation of Anf-luciferase activity was not potentiated by GRP78 overexpression (Figure S6A ), indicating specific relationship between GRP78 and GATA4. Further, we set up to examine whether GRP78 overexpression affected GATA4 protein stability. NRVMs were infected by adenovirus expressing either GFP (green fluorescent protein) or GRP78. Cycloheximide was used to suppress new protein translation. The cells were then harvested at different times to determine GATA4 protein levels. We found that GATA4 protein stability was significantly increased by GRP78 overexpression ( Figure S6B and S6C) . Taken together, these data support a model that GRP78 induction during hypertrophic growth increases GATA4 protein and enhances its transcriptional activity in cardiac myocytes, which may be one of the underlying mechanisms of GRP78-mediated hypertrophic growth in response to pressure overload.
Discussion
GRP78-one of the most abundant protein-folding chaperones 30, 31 -was also discovered as a glucose-regulated protein. 32 At the resting condition, GRP78 binds ER luminal domains of the 3 signaling transducers of the UPR and governs the downstream signaling events. 9 On accumulation of misfolded protein clients, GRP78 exerts its protein-folding action and liberates the sequestration of UPR effectors. As a result, the ER stress response ensues to regain homeostasis. GRP78 is, therefore, not only a master chaperone for protein folding but also a key regulator of the UPR.
Hypertension is one of the most important risk factors of heart failure. In response to high blood pressure, the heart shows extraordinary plasticity and manifests hypertrophic growth to ameliorate ventricular wall stress. 33 It is still a matter of debate whether hypertrophic growth is adaptive or detrimental. Early studies show that suppression of this pressure overload-induced hypertrophic growth by cyclosporine A does not affect cardiac performance. 34 Consistently, treatment with rapamycin-an inhibitor of mTOR signaling-leads to diminishment of cardiac hypertrophic growth and suppression of heart failure development. 35 Even treatment after the establishment of cardiac hypertrophy, rapamycin can rescue cardiomyopathy from pressure overload. 36 These studies together support that cardiac hypertrophic growth is not required to maintain homeostatic function in response to pressure overload. Hypertrophy may, therefore, be a therapeutic target in treatment of hypertensive heart disease.
Accumulating evidence, however, suggests the existence of adaptive hypertrophic growth. Cardiac-specific deletion of mTOR, therefore, eliminating growth in response Figure 5 . Knockdown of GRP78 (glucose-regulated protein of 78 kDa) inhibits cardiomyocyte hypertrophic growth in vitro. A, GRP78 expression was reduced by siRNA-mediated knockdown. Phenylephrine (PE) treatment was conducted for 24 h. Immunofluorescent staining for α-actinin was performed. B, Quantification of (A) showed significant decrease in cell size after GRP78 knockdown. n=80 to 106. C, Leucine incorporation assay showed decrease in protein synthesis after GRP78 silencing. n=4. D, GRP78 knockdown caused reduction in Anf (atrial natriuretic factor) protein expression. E, Quantification of (D) showed a significant decrease in Anf protein level after GRP78 knockdown. n=5. F, GRP78 silencing reduced Anf mRNA expression as assessed by quantitative polymerase chain reaction. n=4 to 5. ctrl indicates control; veh, vehicle; and WB, Western blot. *P<0.05, ***P<0.001.
to pressure overload, is detrimental. 37 The knockout heart progresses into cardiac dilation and failure after TAC. Similarly, cardiomyocyte-restricted knockout of RheB (Ras homolog enriched in brain) or Raptor leads to impaired adaptive growth and cardiomyopathy. 38, 39 The underlying reasons for this discrepancy are not entirely known.
However, pharmaceutical inhibition of growth response, by targeting either NFAT or mTOR, may only partially suppress hypertrophy. In contrast, genetic deletion of mTOR signaling components leads to full elimination of growth response. The different degree of growth inhibition may play a role in these opposite responses. 8 Future work is Figure 6 . GATA4 (GATA-binding protein 4) is required for GRP78 (glucose-regulated protein of 78 kDa)-mediated promotion of hypertrophic growth. A, GATA4 protein expression was increased in the GRP78 transgenic hearts in response to pressure overload. Ctrl (control) and TG (transgenic) mice of 8 to 10 wk of age were subjected to thoracic aortic constriction (TAC), and Western blotting (WB) was performed a week later. n=4. B, GATA4 protein level was upregulated by GRP78 overexpression in neonatal rat ventricular myocytes (NRVMs). GRP78 was overexpressed by adenovirus-mediated infection. The cells were then treated by phenylephrine (PE) for 24 h. n=9. C, GRP78 knockdown led to decrease in GATA4 protein expression. n=5. D, Knockdown of GATA4 in NRVMs diminished GRP78-mediated hypertrophic response. GRP78 was overexpressed by adenoviral infection, and GATA4 was silenced by siRNA transfection. PE treatment was conducted for 24 h. Immunostaining was done to detect α-actinin. n=50 to 80. E, Knockdown of GATA4 reduced GRP78-induced Anf (atrial natriuretic factor) upregulation. F, GRP78 expression enhanced GATA4-dependent Anf promoter activity. An Anf promoter-driven luciferase plasmid was transfected to HEK-293T cells, along with pcDNA3.1 expressing GATA4. Cotransfection of GRP78 led to more profound elevation of luciferase activity, indicating GRP78 potentiates GATA4-dependent Anf induction. n=3 to 4. *P<0.05, ***P<0.001.
warranted to dissect the underlying mechanisms and provide novel targets for therapeutic gain.
To maintain homeostatic performance, hypertrophic heart needs to orchestrate various signaling, more than mere increase in size. Over the past years, numerous pathways and molecules have been identified, including calcium signaling, metabolism, protein synthesis, inflammation, etc. 4 Most of these events are potent inducers of the UPR. 40 Indeed, we show that GRP78, as a master regulator and marker of the UPR, is strongly upregulated. Upstream signal to stimulate the UPR may involve accumulation of misfolded proteins in the ER. On one hand, cardiac cell growth poses a higher demand of protein synthesis/folding, which may trigger the UPR. On the other hand, pathological processes during hypertrophic growth, such as hypoxia and calcium abnormalities, may exacerbate protein misfolding, which adds another layer of burden on ER homeostasis. The UPR and GRP78 upregulation may, therefore, be elicited during cardiac hypertrophic growth.
At both in vivo and in vitro levels, forced overexpression of GRP78 leads to more profound hypertrophic growth of cardiomyocytes. On the contrary, knockdown of GRP78 decreases the growth response in cultured cardiomyocytes. Our further data suggest this response may not involve mTOR and several other established pathways of hypertrophic growth, such as NFAT, ERK, p38, and MEF2. Further, in contrast to the action of GRP78 in cardiac ischemia/reperfusion, 23 GRP78 overexpression does not activate AKT signaling. Interestingly, we show that GATA4 is strongly correlated with GRP78 manipulations, and GRP78 overexpression significantly potentiates GATA4-dependent Anf promoter activity. These findings support our hypothesis that GRP78 may stimulate GATA4 signaling to promoter hypertrophic growth. Previous studies have shown a direct interaction between MEF2 and GATA4 to stimulate Anf expression. 41 Because we did not detect appreciable changes in MEF2, it likely plays a minor role. Questions, however, remain about the molecular mechanisms between GRP78 and GATA4 interaction. GRP78 is mainly localized in the ER, which likely precludes its interaction with transcriptional factor GATA4. However, GRP78 has been discovered in other compartments in the cells, such as plasma membrane and mitochondria. 42 Although nuclear localization has not been validated, it may not be entirely impossible considering the versatile roles of GRP78 recently discovered.
Perspectives
Under hypertensive condition, the heart manifests hypertrophic growth to accommodate ventricular wall stress. We found GRP78-a molecular maker of the UPR-is potently induced by hypertrophic stimuli in cardiomyocytes. Overexpression of GRP78 leads to a higher degree of growth at both in vivo and in vitro levels. Mechanistically, GRP78 may corroborate with GATA4 and promote more profound hypertrophic growth in response to pressure overload.
